Pediatric drug development programs for type 2 diabetes: A review

Journal of Clinical Pharmacology

Volumn 55, Issue 7, 2015, Pages 731-738

  Christensen, Michael L ^a   Franklin, Brandi E ^a   Momper, Jeremiah D ^b   Reed, Michael D ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c AKRON CHILDREN'S HOSPITAL   (United States)

Author keywords

adolescents; clinical trial design; type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE; ANTIDIABETIC AGENT;

ANEMIA; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CHILD; CONGESTIVE HEART FAILURE; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG INDUCED HEADACHE; EDEMA; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; WEIGHT GAIN; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; DRUG DESIGN; DRUG LABELING; UNITED STATES;

CHILD; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; DRUG DESIGN; DRUG LABELING; HUMANS; HYPOGLYCEMIC AGENTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84930654066     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.497     Document Type: Review

References (22)

1. Mulberg AE, Mathis LL, Dunne J, Murphy D,. Introduction pediatric drug development and therapeutics: continued progress for better drugs for children. In: Pediatric Drug Development. 2nd ed. John Wiley & Sons Ltd; 2013: 3-5.
2. Dabelea D, Bell RA, D'Agostino RB Jr, et al., Incidence of diabetes in youth in the United States. JAMA. 2007; 297 (24): 2716-2724.
3. Pettitt DJ, Talton J, Dabelea D, et al., Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. Diabetes Care. 2014; 37 (2): 402-408.
4. Elder DA, Herbers PM, Weis T, Standiford D, Woo JG, D'Alessio DA., beta-Cell dysfunction in adolescents and adults with newly diagnosed type 2 diabetes mellitus. J Pediatr. 2012; 160 (6): 904-910.
5. Gungor N, Arslanian S., Progressive beta cell failure in type 2 diabetes mellitus of youth. J Pediatr. 2004; 144 (5): 656-659.
6. Goran MI, Ball GD, Cruz ML., Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab. 2003; 88 (4): 1417-1427.
7. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA., beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005; 90 (1): 493-500.
8. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care. 2000; 23 (3): 381-389.
9. Weyer C, Bogardus C, Mott DM, Pratley RE., The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999; 104 (6): 787-794.
10. Copeland KC, Silverstein J, Moore KR, et al., Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013; 131 (2): 364-382.
11. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ., Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002; 25 (1): 89-94.
12. Gao X, Christensen M, Burghen GA, et al., Pharmacokinetics of Metformin in Pediatric Type 2 Diabetic and Healthy Adult Subjects. Clin Pharmacol Ther. 2003; 73 (2): P46-P46.
13. Gottschalk M, Danne T, Vlajnic A, Cara JF., Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007; 30 (4): 790-794.
14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry, Non-Inferiority Clinical Trials. Institution; March 2010.
15. D'Agostino RB, Sr., Massaro JM, Sullivan LM,. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat Med. 2003; 22 (2): 169-186.
16. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994; 125 (2): 177-188.
17. Zeitler P, Epstein L, Grey M, et al., Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007; 8 (2): 74-87.
18. Panagiotopoulos C, Riddell M, Sellers E., Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Type 2 Diabetes in Children and Adolescents. Can J Diabetes. 2013; 37 (suppl 3): S341-S342.
19. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M., Type 2 diabetes in the young: the evolving epidemic. The International Diabetes Federation Consensus Workshop. Diabetes Care. 2004; 27 (7): 1798-1811.
20. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Division of Metabolism and Endocrinology Products. Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Institution; February 2008.
21. Kane MP, Abu-Baker A, Busch RS., The utility of oral diabetes medications in type 2 diabetes of the young. Curr Diabetes Rev. 2005; 1 (1): 83-92.
22. Zeitler P, Hirst K, Pyle L, et al., A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012; 366 (24): 2247-2256.